Therefore, it is important that EGFR mutations are detected while screening for drug-sensitive or -resistant NSCLC patients; this is particularly important for Chinese individuals who will undertake targeted therapeutics. This evidence concerns the gene EGFR and non-small cell lung carcinoma.